Over 10 years we help companies reach their financial and branding goals. Engitech is a values-driven technology agency dedicated.

Gallery

Contacts

411 University St, Seattle, USA

+1 -800-456-478-23

News

Myeloid Therapeutics Strengthens its Board of Directors with Two Appointments

Myeloid Therapeutics Strengthens its Board of Directors with Appointments of Stanley Frankel, M.D., FACP and Brett Kaplan, M.D. CAMBRIDGE, Mass, June 30, 2022 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company harnessing the power of myeloid and innate biology to engineer novel therapies that elicit a broad immune response for cancer and autoimmune […]

News

Myeloid Therapeutics to Participate at Investor Conferences in June 2022

CAMBRIDGE, Mass, May 24, 2022 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced that it will participate in the following investor conferences during June 2022: Wells Fargo Private Biotech Symposium, taking place virtually on June 1, 2022 Healthcare Conference, taking place in New […]

News

Myeloid Therapeutics Enters Into Agreement with Acuitas Therapeutics for Lipid Nanoparticle System..

Myeloid Therapeutics Enters Into Agreement with Acuitas Therapeutics for Lipid Nanoparticle (LNP) System, Enabling the First-Ever Delivery of mRNA-Encoded CARs Directly to Humans – Myeloid’s monocyte-specific CAR technology combined with Acuitas’ industry-leading LNP portfolio will accelerate in vivo cell programming for cancer patients – – This strategic step complements Myeloid’s existing pipeline and illustrates its […]

News

Myeloid Therapeutics Doses First Patient with MT-101 in the IMAGINE Phase 1/2 Clinical Study…

Myeloid Therapeutics Doses First Patient with MT-101 in the IMAGINE Phase 1/2 Clinical Study, Marking the First-ever Dosing of an mRNA Engineered CAR Monocyte to Humans -Myeloid dosed MT-101 in a patient with refractory PTCL within 18 months, illustrating the potential of mRNA therapies to help patients sooner and to accelerate Myeloid’s portfolio- -Myeloid achieved […]

News

Myeloid Therapeutics to Participate in Morgan Stanley Private Company Biotech Corporate Access Day

CAMBRIDGE, Mass, April 19, 2022 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced that it will participate in one-on-one and small group meetings with investors at the Morgan Stanley Private Company Biotech Corporate Access Day.The conference is being held in a virtual format […]

News

Myeloid Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Ability of its ATAK™

Late-Breaking Data at AACR 2022: Ability of its ATAK™ Receptors and in vivo Delivery of mRNA to Attack Cancer by Immune Reprogramming CAMBRIDGE, Mass, April 10, 2022 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today presented new late-breaking data at the American Association for […]

News

Myeloid Therapeutics and Prime Medicine Enter Into Exclusive Option and Research Collaboration

to Develop and Accelerate Next-Generation RNA-based Gene-Editing Technology, RetroT™ — Myeloid’s novel RetroT™ technology may enable targeted insertion of gene-sized DNA sequences into the genome, creating new opportunities for programmable gene editing — Myeloid received a $45 million upfront payment from Prime, and is eligible for significant future milestone payments — CAMBRIDGE, Mass, March 31, […]

News

Myeloid Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference

CAMBRIDGE, Mass., March 10, 2022 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced that company management will present a corporate overview at Oppenheimer’s 32nd Annual Healthcare Conference and will participate in one-on-one meetings with investors. The conference is being held in a […]

News

Myeloid Therapeutics Announces Late-Breaking Presentations at AACR 2022 Annual Meeting

Late-Breaking Presentations on mRNA in-vivo Delivery and ATAK™ CAR Receptors CAMBRIDGE, Mass., March 9, 2022 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced that it will present two late-breaking posters at the American Association for Cancer Research (AACR) Annual Meeting taking place […]